|
If you suspect it's Alzheimer's, Nymox Pharmaceutical can help prove it. The firm markets AlzheimAlert, a urine test to measure neural thread protein levels (found in large amounts in Alzheimer's disease patient samples) to assist physicians in the early diagnosis of the condition in the US and Europe. It also makes the NicAlert and TobacAlert tobacco exposure diagnostic tests through subsidiary Serex. In addition, Nymox is developing therapeutic drugs to treat ailments such as Alzheimer's disease, enlarged prostate, and bacterial infections. The company also has additional diagnostic products under development.
|
| | | Contact Information | |
Address: |
9900 Cavendish Blvd., Ste. 306
Saint-Laurent, Quebec H4M 2V2, Canada
| | Phone: | 514-3323222 | | Fax: | 514-3322227 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.40 M | | Revenue Growth (1 yr): | (-1.30%) | | Employees (2008): | 21 | | Employee Growth (1 yr): | 10.50% |
|
|
Key People
| | • |
President, CEO, and Director:
Paul Averback
| | • |
CFO, Secretary, Treasurer, and Director:
Roy M. Wolvin
| | • |
Senior Manager, Global Sales and Marketing:
Brian Doyle
|
|
|
